Patents by Inventor Detlev Sülzle

Detlev Sülzle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250170136
    Abstract: The present invention includes name compounds of general formula (I): (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.
    Type: Application
    Filed: January 21, 2025
    Publication date: May 29, 2025
    Applicants: BAYER AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC.
    Inventors: Stefan Nikolaus Gradl, Manuel Ellermann, Philip Lienau, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu
  • Publication number: 20250136599
    Abstract: Compounds of formula (I), formula (I), processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: November 15, 2024
    Publication date: May 1, 2025
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan Siegel, Franziska Siegel, Volker Schulze, Markus Berger, Keith Graham, Detlev Sülzle, Ulf Bömer, Daniel Korr, Jens Schröder, Ursula Mönning, Michael Niehues, Matthew Meyerson, Heidi Greulich, Bethany Kaplan
  • Patent number: 12258323
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: March 25, 2025
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Patent number: 12227501
    Abstract: The present invention relates to compounds of formula (I) processes for their production and their use as pharmaceuticals. The compounds are inhibitors of Casein kinase 1 alpha and/or delta (CSNK1? and/or ?) useful for the treatment of proliferative disorders.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: February 18, 2025
    Assignees: Bayer Aktiengesellschaft, Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Volker Schulze, Anne Mengel, Jens Schröder, Adelaide Clara Faria Alvares De Lemos, Wilhelm Bone, Ulf Bömer, Detlev Sülzle, Clara Christ, Roman Hillig, Christian Lechner, Steven Corsello, Katarzyna Handing, Alisha Caliman, Ulrike Rauh, Stefan Kaulfuss, Jérémie Xavier G. Mortier
  • Publication number: 20250042863
    Abstract: The present invention relates to a novel process for preparing isoxazolinecarboxylic acid derivatives of the formula (I).
    Type: Application
    Filed: December 1, 2022
    Publication date: February 6, 2025
    Inventors: Denise CIBU, Diana Isabel YEPES TEJADA, Anton LISHCHYNSKYI, Michael Edmund BECK, Mark James FORD, Frank MEMMEL, Andreas REMBIAK, Detlev SÜLZLE
  • Publication number: 20240307362
    Abstract: Compounds of formula (I), processes for their production and their use as pharmaceuticals are described herein.
    Type: Application
    Filed: April 22, 2020
    Publication date: September 19, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Stefan Nikolaus GRADL, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN, Hassan Youssef HARB, Phi Manh DINH
  • Publication number: 20240182452
    Abstract: The present invention provides dihydropyridazinone compounds of general formula (I) in which R1, R2 and R3 are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: December 28, 2023
    Publication date: June 6, 2024
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Detlev SÜLZLE, Timothy LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON
  • Publication number: 20240150277
    Abstract: The present invention includes compounds of formula (I) and methods for its preparation and treatment of disorders with activated peroxisome preoliferator-activated receptor gamma (PPARG), particularly cancer.
    Type: Application
    Filed: August 31, 2023
    Publication date: May 9, 2024
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Knut EIS, Timo STELLFELD, Léa Aurelie BOUCHÉ, Elisabeth POOK, Joseph Peter BLUCK, Philip LIENAU, Constantia PANTELIDOU, Isabel Sophie JERCHEL-FURAU, Ulf BRÜEGGEMEIER, Sven CHRISTIAN, Detlev SÜLZLE, Anders Roland FRIBERG, Simon HOLTON, Christian LECHNER, Stefan KAULFUSS, Hanna MEYER, Douglas ORSI, Steven James FERRARA, Jonathan GOLDSTEIN, Matthew MEYERSON, Christopher LEMKE
  • Publication number: 20230416249
    Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: May 10, 2023
    Publication date: December 28, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Ulrich KLAR, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
  • Publication number: 20230365554
    Abstract: Compounds of formula (I), process for their production and their use as pharmaceuticals.
    Type: Application
    Filed: July 27, 2021
    Publication date: November 16, 2023
    Inventors: Volker Schulze, Anne Mengel, Adelaide Clara Faria Alvares De Lemos, Ulrike Rauh, Ulf Bömer, Roman Hillig, Christian Lechner, Jeremie Xavier G. Mortier, Detlev Sülzle, Stefan Kaulfuss, Steven Corsello, Katarzyna Handing, Alisha Caliman, Amael Madec
  • Patent number: 11773070
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: July 14, 2022
    Date of Patent: October 3, 2023
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Publication number: 20230064983
    Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: September 22, 2022
    Publication date: March 2, 2023
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Jeremie Xavier G. MORTIER, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
  • Publication number: 20230017200
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 11, 2022
    Publication date: January 19, 2023
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
  • Publication number: 20220396554
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I) in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: July 14, 2022
    Publication date: December 15, 2022
    Applicants: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel ELLERMANN, Stefan Nikolaus GRADL, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Philip LIENAU, Christa HEGELE-HARTUNG, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU, Matthew MEYERSON, Alex BURGIN
  • Publication number: 20220298157
    Abstract: Compounds of formula (I), formula (I), processes for their production and their R use as pharmaceuticals.
    Type: Application
    Filed: April 22, 2020
    Publication date: September 22, 2022
    Applicants: Bayer Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Stephan SIEGEL, Franziska SIEGEL, Volker SCHULZE, Markus BERGER, Keith GRAHAM, Detlev SÜLZLE, Ulf BÖMER, Daniel KORR, Jens SCHRÖDER, Ursula MÖNNING, Michael NIEHUES, Matthew MEYERSON, Heidi GREULICH, Bethany KAPLAN
  • Patent number: 11427553
    Abstract: The present invention provides dihydrooxydiazinone compounds of general formula (I): in which R1, R2, R3, and R4, are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative diseases, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 2, 2018
    Date of Patent: August 30, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc.
    Inventors: Manuel Ellermann, Stefan Nikolaus Gradl, Charlotte Christine Kopitz, Martin Lange, Adrian Tersteegen, Philip Lienau, Christa Hegele-Hartung, Detlev Sülzle, Timothy A. Lewis, Heidi Greulich, Xiaoyun Wu, Matthew Meyerson, Alex Burgin
  • Patent number: 11339157
    Abstract: Compounds of formula (I) processes for their production and their use as pharmaceuticals.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 24, 2022
    Assignees: Bayer Aktiengesellschaft, Bayer Pharma Aktiengesellschaft, Dana-Farber Cancer Institute, Inc., The Broad Institute, Inc.
    Inventors: Stephan Siegel, Franziska Siegel, Volker Schulze, Markus Berger, Keith Graham, Ulrich Klar, Knut Eis, Detlev Sülzle, Ulf Bömer, Daniel Korr, Kirstin Petersen, Ursula Mönning, Uwe Eberspächer, Dieter Moosmayer, Matthew Meyerson, Heidi Greulich, Bethany Kaplan, Hassan Youssef Harb, Phi Manh Dinh
  • Patent number: 11311520
    Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: August 3, 2020
    Date of Patent: April 26, 2022
    Assignees: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich Klar, Rolf Bohlmann, Heike Schäcke, Detlev Sülzle, Stephan Menz, Olaf Panknin
  • Publication number: 20210353630
    Abstract: The present invention includes name compounds of general formula (I): (I) in which R1, R2, R3 and R4 are as defined herein, methods for their preparation, pharmaceutical compositions and combinations comprising said compounds, and their use for the treatment of hyperproliferative diseases.
    Type: Application
    Filed: July 30, 2021
    Publication date: November 18, 2021
    Applicants: BAYER AKTIENGESELLSCHAFT, THE BROAD INSTITUTE, INC.
    Inventors: Stefan Nikolaus GRADL, Manuel ELLERMANN, Philip LIENAU, Charlotte Christine KOPITZ, Martin LANGE, Adrian TERSTEEGEN, Detlev SÜLZLE, Timothy A. LEWIS, Heidi GREULICH, Xiaoyun WU
  • Publication number: 20210085656
    Abstract: The present invention relates to substituted dihydroimidazopyridinedione compounds of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyperproliferative, angiogenesis disorders, inflammatory diseases or diseases associated with inflammatory pain, as a sole agent or in combination with other active ingredients.
    Type: Application
    Filed: August 3, 2020
    Publication date: March 25, 2021
    Applicants: Bayer Pharma Aktiengesellschaft, Bayer Aktiengesellschaft
    Inventors: Ulrich KLAR, Rolf BOHLMANN, Heike SCHÄCKE, Detlev SÜLZLE, Stephan MENZ, Olaf PANKNIN